- The company will demonstrate its capabilities as a contract development and manufacturing organization (CDMO) specializing in small molecule APIs and intermediates with over 40 years’ industry experience.
- AGC Pharma Chemicals is committed to its European site and is stepping up expansion plans with a €90M investment in its Barcelona facility
- The capital will further boost the multi-purpose plant characterised by high reliability, flexibility, agility and competitiveness
Barcelona, October 28th 2022.- AGC Pharma Chemicals will land at CPHI Frankfurt 2022 with the aim of showcasing its innovative solutions and extensive capabilities as a small molecule CDMO of active pharmaceutical ingredients (APIs) and intermediates. From 1 to 3 November, the company will be physically present at Stand 9.1 B50, a meeting point for prospective customers and strategic suppliers interested in the company.
From its European headquarters in Barcelona, the company transfers an important team to CPHI Frankfurt. The team will be led by Akihiro Kadokura, CEO of AGC Pharma Chemicals, Tom De Geyter, its Director of Sales and Business Development, and a strong selection of members from the purchasing, sales and marketing team.
A trusted small molecule CDMO partner for the development and manufacture of active pharma ingredients and intermediates
AGC Pharma Chemicals is distinguished in the market as an international contract development and manufacturing organization producing small-molecule APIs and intermediate products at its production sites in Spain and Japan.
Reliability is among its core strengths and the company’s track record shows it has had no FDA 483 observations for over 20 years. Its many capabilities include agility and flexibility in decision-making enabled by having all functions covered at its multi-purpose plant in Malgrat de Mar (Barcelona province). The firm’s highly qualified R&D chemists create and validate synthetic routes to deliver pharmaceutical pipelines with no surprises or delays.
Last April, the company announced a €90M investment to expand its Barcelona plant, creating 100 new jobs. Thanks to the financial stability of the AGC Group, the company plans to continue stepping up its capabilities.
The expansion of the CDMO consists of building a 7,500 m3 facility with reactors of up to 7.5 cubic meters, designed to produce HAPI pharmaceutical compounds.
In terms of sustainability, as a member of the Responsible Care® Program (a voluntary initiative by the global chemical industry) AGC Pharma Chemicals will build and operate the new plant minimizing its environmental impacts.
